Results 221 to 230 of about 45,216 (237)

Immunotherapies for hepatocellular carcinoma

Nature Reviews Clinical Oncology, 2021
, Florian Castet, Mala K Maini
exaly  

The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects

Signal Transduction and Targeted Therapy, 2020
Weiwei Tang, Fan Wu, Qian Wang
exaly  

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Lancet Oncology, The, 2022
Thomas Yau, Joong-Won Park, Richard S Finn   +2 more
exaly  

Recent Progress in the Management of Advanced Renal Cell Carcinoma

Ca-A Cancer Journal for Clinicians, 2007
Brian I Rini
exaly  

m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance

Signal Transduction and Targeted Therapy, 2020
Daimin Xiang, Cheng Zhang, Hong-Yang Wang   +2 more
exaly  

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Lancet, The, 2018
Matsatoshi Kudo, Kwang-Hyub Han, Fabio Piscaglia   +2 more
exaly  

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2017
Jordi Bruix, Shukui Qin, Philippe Merle
exaly  

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

Gut, 2020
Matsatoshi Kudo, Masafumi Ikeda, Takuji Torimura   +2 more
exaly  

Molecular therapies and precision medicine for hepatocellular carcinoma

Nature Reviews Clinical Oncology, 2018
, Daniela Sia, Richard S Finn
exaly  

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Lancet Oncology, The, 2009
Ann-Lii Cheng, Yoon-Koo Kang, Shukui Qin
exaly